Abstracts tagged "Interferons and systemic lupus erythematosus (SLE)"

Abstract Number: 1634 • 2013 ACR/ARHP Annual Meeting
Genome-Wide Transcriptional Profiling Of Isolated Immune Cell Populations From SLE Patients With Different Ancestral Backgrounds
Shruti Sharma¹, Zhongbo Jin², Elizabeth Rosenzweig³, Swapna Rao⁴, Kichul Ko⁴ and Timothy B. Niewold², ¹Gwen Knapp Center for Lupus Research, University of Chicago, Chicago, IL, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁴Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex multi-system autoimmune disease of uncertain etiology. Different ancestral backgrounds demonstrate different clinical manifestations and autoantibody profiles. Whole…
Abstract Number: 1609 • 2013 ACR/ARHP Annual Meeting
AMG 811 (anti-IFN-gamma) Treatment Leads To a Reduction In The Whole Blood IFN-Signature and Serum CXCL10 In Subjects With Systemic Lupus Erythematosus: Results Of Two Phase I Studies
David A. Martin¹, Andrew Welcher², Michael Boedigheimer², Zahir Amoura³, Alan Kivitz⁴, Jill P. Buyon⁵, Jorge Sanchez-Guerrero⁶, Juanita Romero-Diaz⁷, Alla Rudinskaya⁸, Kevin M. Latinis⁹, S Cohen¹⁰, Cynthia Aranow¹¹, Mike Damore², Winnie Sohn², Kit Chiu², Christine Wang¹², Naren Chirmule², Barbara Sullivan² and James Chung², ¹Medical Sciences, Amgen, Seattle, WA, ²Amgen, Thousand Oaks, CA, ³Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Danbury Hospital, Danbury, CT, ⁹Latinis Rheumatology, Leawood, KS, ¹⁰Metroplex Clinical Research Center, Dallas, TX, ¹¹The Feinstein Institute, Manhasset, NY, ¹²Biostatistics, Amgen, Thousand Oaks, CA
Background/Purpose: Interferon-gamma (IFN-g) is a major pro-inflammatory cytokine that modulates the function of several important populations of immune cells including B cells, T cells, and…
Abstract Number: 1601 • 2013 ACR/ARHP Annual Meeting
The Presence Of IgG-Immune Complexes In The Cerebrospinal Fluids Is Associated With Central Neurocychiatric Manifestatin But Not With Intrathecal Production Of Proimmflammatory Cytokines/Chemokines Such as Interferon-α In Systemic Lupus Erythematosus
Taku Yoshio¹, Hiroshi Okamoto², Kazuhiro Kurasawa³, Yoshiaki Dei⁴, Shunsei Hirohata⁵ and Seiji Minota⁶, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, ²Minami-Otsuka Institute of Thechnology, Minami-Otsuka Clinic, Tokyo, Japan, ³Clinical Immunology, Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi-ken, Japan, ⁴Saiseikai Utsunomiya Hospital, Utsunomiya-shi, Tochigi-ken, Japan, ⁵Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, ⁶Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan
Background/Purpose: IgG-Immune complexes (IC) formed by CSF autoantibodies in patients with neuropsychiatric syndromes of systemic lupus erythematosus (NPSLE) has reported to stimulate the production of…
Abstract Number: 1576 • 2013 ACR/ARHP Annual Meeting
Type I Interferon-Mediated Skewing Of The Serotonin Synthesis In Systemic Lupus Erythematosus Is Associated To Cardiovascular Disease
Christian Lood¹, Helena Tydén¹, Birgitta Gullstrand², Cecilia Klint³, Christina Wenglén³, Christoffer T. Nielsen⁴, Niels H. H. Heegaard⁵, Andreas Jönsen¹ and Anders A. Bengtsson¹, ¹Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Department of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden, ³R&D, AnaMar AB, Lund, Sweden, ⁴Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen S, Denmark, ⁵Department of Clinical Biochemistry, Immunology & Genetics, Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by increased expression of type I interferons (IFNs). Indoleamine 2,3-dioxygenase (IDO), a type I…
Abstract Number: 642 • 2013 ACR/ARHP Annual Meeting
Serum Concentrations Of Type I Interferon-Regulated Chemokines Are Associated With Disease Activity In Systemic Lupus Erythematosus
Eric F. Morand, Kathryn Connelly and Alberta Y. Hoi, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia
Background/Purpose: Expression array studies suggest the activity of Type I interferon (IFN), as reflected in IFN-induced genes, is associated with phenotypic subsets in SLE. Three…
Abstract Number: 36 • 2013 ACR/ARHP Annual Meeting
IFN-α Induces Altered Transitional B Cell Signaling and Function In Systemic Lupus Erythematosus
Joan E. Wither¹, Nan-Hua Chang², Timothy Li³, Julie Kim⁴, Carolina Landolt-Marticorena⁵, Paul R. Fortin⁶, Dafna D. Gladman⁷ and Murray B. Urowitz⁸, ¹1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁶Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Previous experiments suggest that the B cells of lupus patients are hyper-responsive to B cell receptor engagement resulting in increased tyrosine phosphorylation and Ca2+mobilization. …
Abstract Number: 1741 • 2013 ACR/ARHP Annual Meeting
Correlation Of The Interferon Gene Signature With Systemic Lupus Erythematosus Disease Activity Is Dependent On The Associated Level Of The BAFF Gene Transcript
Michelle Petri¹, Laurence S. Magder², Hong Fang¹, Julie Czerkowicz³, Andrea Dearth³, Jadwiga Bienkowska⁴, Norm Allaire⁵, Patrick Cullen³, Alice Thai³ and Ann Ranger³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Biogen Idec Inc, Cambridge, MA, ⁴Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁵Biogen Idec Inc., Cambridge, MA
Background/Purpose: The interferon alpha (IFN) gene signature is frequent in SLE (~50% of patients) and important in pathogenesis. However, multiple studies have found that the…
Abstract Number: 2622 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Rontalizumab (Anti-Interferon Alpha) in SLE Subjects with Restricted Immunosuppressant Use: Results of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study
K. Kalunian¹, Joan T. Merrill², R. Maciuca³, Wenjun Ouyang³, J. M. McBride³, Michael J. Townsend³, E. Park³, J. Li³, X. Wei³, A. Morimoto³, R. Boismenu³, John C. Davis Jr.³ and William P. Kennedy³, ¹UCSD School of Medicine, La Jolla, CA, ²Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Genentech, Inc, South San Francisco, CA
Background/Purpose: Dysregulation of interferon alpha (IFN) activity and/or signaling is implicated in systemic lupus (SLE). This randomized, double-blind, placebo-controlled, two part Phase 2 study (ROSE)…
Abstract Number: 2271 • 2012 ACR/ARHP Annual Meeting
Variation of Interferon-Alpha Production in Healthy Individuals and Association with Autoimmune Susceptibility Genes
Olof Berggren¹, Andrei Alexsson², Gunnar V. Alm³, Ann-Christine Syvänen⁴, Lars Rönnblom² and Maija-Leena Eloranta², ¹Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ³Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences, Uppsala, Sweden, ⁴Department of Medical Sciences, Molecular Medicine, Uppsala University, Uppsala, Sweden
Background/Purpose: Many autoimmune diseases, e.g. systemic lupus erythematosus (SLE), have an activated type I interferon (IFN) system and about 40 SLE susceptibility loci, many within…
Abstract Number: 1809 • 2012 ACR/ARHP Annual Meeting
Serum IFNα Activity in Systemic Lupus Erythematosus Drops in Response to Immunosuppressive Therapy Only When There Is Concurrent Clinical Response
Elzbieta E. Jacek¹, Elena Gkrouzman¹, Mikhail Olferiev¹, Nancy Pan², Roland Duculan³, Kyriakos A. Kirou¹ and Mary K. Crow⁴, ¹Hospital for Special Surgery, New York, NY, ²Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ³Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, Hospital for Special Surgery, New York, NY, ⁴Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: The type I interferon (IFN-I) signature, describing expression in PBMC of a large set of gene transcripts induced by IFN-I, and increased serum IFNα…
Abstract Number: 1456 • 2012 ACR/ARHP Annual Meeting
A Tolerogenic Peptide Down-Regulates the Expression of Interferon-a in Murine and Human Systemic Lupus Erythematosus
Zev M. Sthoeger¹, Heidy Zinger², Amir Sharabi², Ilan Asher¹ and Edna Mozes², ¹Department of Medicine, Kaplan Hospital, Rehovot, Israel, ²The Weizmann institute of Science, Rehovot, Israel
Background/Purpose: The tolerogenic peptide, designated hCDR1, was shown to ameliorate manifestations of systemic lupus erythematosus (SLE) via down-regulation of pro-inflammatory cytokines, up-regulation of immunosuppressive cytokines…
Abstract Number: 1081 • 2012 ACR/ARHP Annual Meeting
Toll-Like Receptor 7, 8 and 9 Activation of Primary Human Cells by Lupus Immune Complexes Is Dependent On Interleukin 1 Receptor Associated Kinase 4 Activity
Aaron Winkler¹, Weiyong Sun¹, Ken Dower², Elizabeth A. Murphy¹, Julia Shin¹, Michael Luong¹, Michael J. Primiano¹, Varenka A. Rodriguez², Tatyana Souza¹, Lih-Ling Lin³, J. Perry Hall¹, Katherine Lee⁴, Vikram R. Rao¹ and Margaret Fleming¹, ¹Inflammation & Remodeling, Pfizer, Cambridge, MA, ²Inflammation and Remodeling, Pfizer, Cambridge, MA, ³Inflammation and Remodeling Research Unit, Pfizer, Cambridge, MA, ⁴Worldwide Medicinal Chemistry, Pfizer, Cambridge, MA
Background/Purpose: Genetic, in vitro and in vivo evidence strongly implicate the activation of nucleic acid sensing toll like receptors (TLR) 7, 8, and 9 in…
Abstract Number: 979 • 2012 ACR/ARHP Annual Meeting
Cell-Type Specific Type I Interferon Signatures in Systemic Lupus Erythematosus and Viral Infection: What Makes the Difference?
Chieko Kyogoku¹, Joachim R. Grün¹, Tobias Alexander², Robert Biesen³, Falk Hiepe⁴, Thomas Häupl³, Andreas Radbruch¹ and Andreas Grützkau¹, ¹German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ⁴Med. Klinik m. Sp. Rheumatologie und klin. Immunologie, Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Gene expression profiling experiments using peripheral blood mononuclear cells (PBMCs) revealed a crucial role of type I interferon (IFN) in the pathogenesis of systemic…
Abstract Number: 686 • 2012 ACR/ARHP Annual Meeting
Cell-Type Specific Type I Interferon Signatures in Autologous Stem Cell Transplanted Lupus Patients: Different Molecular Behavior Between CD4+ T Cells and Monocytes
Chieko Kyogoku¹, Joachim R. Grün¹, Tobias Alexander², Robert Biesen³, Falk Hiepe⁴, Thomas Häupl³, Andreas Radbruch¹ and Andreas Grützkau¹, ¹German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Germany, ³department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ⁴Med. Klinik m. Sp. Rheumatologie und klin. Immunologie, Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that affects multiple organs, whose pathology is mainly caused by the augmented interferon (IFN)…
Abstract Number: 667 • 2012 ACR/ARHP Annual Meeting
Interferon-Alpha Impairs the Survival and Function of Circulating Angiogenic Cells in Vitro: A Model of Failed Endothelial Repair in SLE
John A. Reynolds¹, David W. Ray², Terence O'Neill³, M. Yvonne Alexander⁴ and Ian N. Bruce⁵, ¹Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, ²Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁴Healthcare Science Research Institute, Faculty of Science and Engineering, Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Patients with Systemic Lupus Erythematosus have an increased risk of cardiovascular disease (CVD). No specific targeted therapies for CVD in lupus exist and there…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].